The European Network for the Study of Adrenal Tumors Staging System (2015): A United States Validation
Authors' conclusion
The accuracy of mENSAT is virtually the same as that of AJCC in predicting CSM (74.7% vs 74.5%) and OM (73.7% vs 73.5%). However, calibration is lower for mENSAT than for AJCC. In consequence, no obvious benefit appears to be associated with the use of mENSAT relative to AJCC in US ACC patients.
Study context
- Population
- Adrenocortical carcinoma (ACC) patients of all stages, Surveillance, Epidemiology, and End Results (SEER) database (2004–2020)
- Participants
- 858 patients
- Exposure
- mENSAT vs AJCC 8th edition staging
- Outcome
- Accuracy and calibration in predicting cancer-specific mortality (CSM) and overall mortality (OM)
- Follow-up
- 3-year
Methodological detailspopulation-based, staging system validation
- Population-based
- Staging system validation
Main finding
As reported in the abstract
Accuracy for 3-year CSM predictions
Observational data: associations, not effects.
Further findings
Accuracy for 3-year OM predictions
| Outcome | mENSAT | AJCC |
|---|---|---|
| Calibration: maximum departure from ideal predictions | ||
| CSM | +17.2% | −6.7% |
| OM | +11.8% | −7.1% |
Original publication
The European Network for the Study of Adrenal Tumors Staging System (2015): A United States Validation. J Clin Endocrinol Metab. Published 24 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →